BioCentury | Jan 10, 2005
Finance

Ebb & Flow

Last week saw two series D rounds go in opposite directions. Cancer play Nereus opted for a two-part financing, and maintains that having milestone-contingent money is important for discipline. On the flip side, drug delivery...
BioCentury | Nov 4, 2002
Finance

Ebb & Flow

Equities - including biotech - put in a good showing in the first month of the fourth quarter, providing an especially upbeat sign given that October is typically the worst month of the year for equities (see...
BC Extra | Oct 31, 2002
Financial News

Pieris raises EUR12 million

Pieris Proteolab (Freising, Germany) raised EUR12 million ($11.7 million) in a series A round led by Global Life Science Ventures; and Gilde Investment Management. Other investors included BayTech Venture Capital; ABN AMRO; BioM; and TransConnect....
Items per page:
1 - 3 of 3
BioCentury | Jan 10, 2005
Finance

Ebb & Flow

Last week saw two series D rounds go in opposite directions. Cancer play Nereus opted for a two-part financing, and maintains that having milestone-contingent money is important for discipline. On the flip side, drug delivery...
BioCentury | Nov 4, 2002
Finance

Ebb & Flow

Equities - including biotech - put in a good showing in the first month of the fourth quarter, providing an especially upbeat sign given that October is typically the worst month of the year for equities (see...
BC Extra | Oct 31, 2002
Financial News

Pieris raises EUR12 million

Pieris Proteolab (Freising, Germany) raised EUR12 million ($11.7 million) in a series A round led by Global Life Science Ventures; and Gilde Investment Management. Other investors included BayTech Venture Capital; ABN AMRO; BioM; and TransConnect....
Items per page:
1 - 3 of 3